STAT April 30, 2024
Blythe Adamson

Next-generation broadly neutralizing antibodies (bnAbs) have the potential to transform the fight against global health threats like HIV, malaria, and Ebola. The commercialization of these innovative antibody therapies could save millions of lives annually. But turning promise into reality requires foresight and commitment.

Broadly neutralizing antibodies are a type of protein that can recognize and neutralize a wide range of pathogens, including multiple strains of viruses such as HIV. This versatility makes them highly valuable in medicine, promising effective treatments and preventive measures against infectious diseases. New discoveries are improving the potency and durability of antibodies in general.

But significant roadblocks, particularly concerning manufacturing investments, impede the path of antibody therapies from the lab to the clinic. The cost of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Pharma, Pharma / Biotech, Public Health / COVID
Bipartisan scrutiny of health care mergers
Prescriptions Are Up, Health Services Utilization Down, and GLP-1s Are a Major Growth Driver: IQVIA’s 2024 Update
Ipilimumab, a Pioneer Breakthrough in Cancer Treatment
AZ plots $1.5B antibody-drug conjugate plant in Asia
STAT+: AI & drug discovery: A biotech CEO, a scientist, and a venture capitalist separate hype from reality

Share This Article